Month 3: Established routine and noticeable results motivate continued healthy choices
And it's getting expensive
Clinical trials consistently demonstrate that once-weekly TZP leads to substantial and sustained reductions in body weight often exceeding 15%20% and marked improvements in glycaemic control, with reductions in HbA1c surpassing many existing therapies
Comparisons to Other GLP-1 Analogs Compared to other GLP-1 analogs, Semaglutide offers several advantages
Safety and Clinical Management Safety trials of GLP-1 RAs, including liraglutide, tirzepatide, and semaglutide (oral or subcutaneous), indicate that the most common adverse events (AEs) of treatment are mild to moderate gastrointestinal including nausea, vomiting, diarrhea, constipation, dyspepsia, and decreased appetite